Future Directions for Personalized Care in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Jason Mouabbi and Dr. Seth Wander discuss future opportunities to refine biomarker-driven treatment approaches for patients with HR-positive, HER2-negative advanced breast cancer. The experts highlight the importance of real-world evidence in complementing clinical trial findings and providing additional insight into treatment sequencing, timing of intervention, and patient outcomes in routine practice. Dr. Wander emphasizes the expanding role of personalized oncology, including the importance of understanding ESR1 mutations, PI3K pathway alterations, germline BRCA status, and HER2 expression when selecting therapies across later lines of treatment. The discussion explores how earlier identification of resistance mechanisms may continue to shape future clinical trial designs and individualized treatment strategies. Dr. Wander concludes by highlighting the need for ongoing biomarker assessment and continued progress toward more personalized approaches that optimize outcomes and quality of life for patients with HR-positive, HER2-negative advanced breast cancer.